TY  - CHAP
M1  - Book, Section
TI  - Thyroid Disorders
A1  - Katz, Michael D.
A2  - Chisholm-Burns, Marie A.
A2  - Schwinghammer, Terry L.
A2  - Malone, Patrick M.
A2  - Kolesar, Jill M.
A2  - Bookstaver, P. Brandon
A2  - Lee, Kelly C.
PY  - 2022
T2  - Pharmacotherapy Principles & Practice, 6e
AB  - LEARNING  OBJECTIVESUpon  completion  of  the  chapter,  the  reader  will  be  able  to:Discuss  the  prevalence  of  common  thyroid  disorders,  including  mild  and  overt  hypothyroidism  and  hyperthyroidism.Explain  the  major  components  of  the  hypothalamic–pituitary–thyroid  axis  and  interaction  among  these  components.Discuss  the  relationship  between  serum  thyroid-stimulating  hormone  (TSH)  levels  and  primary  thyroid  disease,  and  advantages  for  the  use  of  TSH  levels  over  other  tests  such  as  serum  T4  (thyroxine)  and  T3  (triiodothyronine)  levels.Identify  typical  signs  and  symptoms  of  hypothyroidism  and  consequences  of  suboptimal  treatment.Describe  clinical  use  of  levothyroxine  (LT4)  in  the  treatment  of  hypothyroidism.Discuss  issues  regarding  LT4  product  bioequivalence  and  reasons  for  maintaining  patients  on  the  same  product.Describe  the  management  of  hypothyroidism  and  hyperthyroidism  in  special  populations,  including  pregnant  women.Identify  typical  signs  and  symptoms  of  Graves  disease  and  consequences  of  inadequate  treatment.Discuss  the  pharmacotherapy  of  Graves  disease,  including  advantages  and  disadvantages  of  antithyroid  drugs  versus  radioactive  iodine,  adverse  effects,  and  patient  monitoring.Describe  potential  effects  of  selected  drugs  including  amiodarone,  lithium,  interferon-α,  tyrosine  kinase  inhibitors  (TKIs),  and  immune  checkpoint  inhibitors  on  thyroid  function.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2025/01/12
UR  - ppp.mhmedical.com/content.aspx?aid=1187015986
ER  -